Q3 2025 EyePoint Pharmaceuticals Inc Earnings Call Transcript

Nov 5, 2025 / 01:30 PM GMT

Release Date Price: €10.6 (-2.35%)

Transcript 10-Q8-K

Key Points

Positve

EyePoint Pharmaceuticals Inc (EYPT) has completed enrollment for its phase 3 trials, Lugano and Lucia, for Dureview in wet AMD, recruiting over 900 patients in just 7 months.
The company has aligned with the FDA on a non-inferiority trial design for DME, which is considered clinically rigorous and de-risked.
EyePoint Pharmaceuticals Inc (EYPT) ended September 2025 with over $200 million in cash and equivalents, and a $172 million follow-on offering in October, extending operational funding into Q4 2027.
Dureview is positioned as the first to file and first to market among investigational sustained delivery programs for wet AMD and DME, potentially offering a first-mover advantage.
The company has a strong manufacturing capability with a GMP-compliant facility in Northbridge, Massachusetts, ready to support commercial launch.

Negative

Total net revenue for the quarter ended September 30, 2025, was $1 million, a significant decrease from $10.5 million in the same quarter of 2024.
Operating expenses increased to $63 million for the quarter ended September 30, 2025, compared to $43.3 million in the prior year, primarily due to clinical trial costs.
Net loss for the quarter was $59.7 million, or $0.85 per share, compared to a net loss of $29.4 million, or $0.54 per share, in the prior year period.
The company's cash and investments decreased from $371 million as of December 31, 2024, to $204 million as of September 30, 2025.
There is uncertainty regarding the exact market share and adoption rate of Dureview, as it depends on the acceptance of its multi-MOA and sustained release features by physicians and patients.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

EYPT.OQ - EyePoint Pharmaceuticals Inc
Q3 2025 EyePoint Pharmaceuticals Inc Earnings Call
Nov 05, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning. My name is Antoine, and I will be your conference operator today.

At this time, I would like to welcome everyone to the IPoint 3rd quarter, 2025 financial results and recent corporate developments conference call. There will be a question-and-answer session to follow at the completion of the prepared remarks.

Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to George Elston, executive Vice President and Chief Financial Officer of IPoint. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
----------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.